西藏珠峯(600338.SH):塔城國際所持1663.2萬股將被司法處置
格隆匯7月2日丨西藏珠峯(600338.SH)公佈,近日,公司從上海金融法院微信公眾號獲悉,上海金融法院將於2021年7月16日在司法執行平台再次就上述處置標的物公開進行股票司法處置。
此次處置標的物為塔城國際資源持有的公司股票共計1663.2萬股股份;此次處置競買人繳納保證金應於2021年7月5日起至2021年7月13日15:30前支付;競買出價時間為2021年7月16日9:30至11:30、13:00至15:30。此次股票的處置起始單價為2021年7月16日前二十個交易日該股票收盤平均價的90%,未超過處置起始單價的競買出價無效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.